Licensee Evelo Therapeutics will advance an immunotherapy developed by University of Chicago oncologist Thomas Gajewski that employs certain gut microbes to boost the immune system’s attack on cancer cells and improve the effectiveness of anti-cancer drugs. Evelo, Gajewski, and UChicago will work together to bring this technology to the patient setting as quickly as possible, while continuing to explore the mechanisms of the microbiome in cancer.
- Principal Investigator – Tom Gajewski
- Deal Date – 2016
- Industry — Microbiome
- Current Status — Venture backed
- Learn more about Evelo Therapeutics in this press releases